[CAS NO. 101238-54-4] Levemopamil hydrochloride
PRODUCTS SPECIFICATIONS [101238-54-4]
DESCRIPTION [101238-54-4]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 370.96 |
| Molecular Formula | C23H31ClN2 |
| SMILES | CN(CCC1=CC=CC=C1)CCC[C@@](C#N)(C2=CC=CC=C2)C(C)C.Cl |
Summary
Levemopamil hydrochloride is a blood-brain barrier penetrable calcium channel blocker and a 5-HT2 antagonist. Levemopamil hydrochloride can be used for temporary occlusion and neurological disease research [1] .
In Vivo
Levemopamil hydrochloride (30 mg/kg; i.p., once) regulates bilateral damping of carotid arteries (BCCA) process and reduces spatial memory deficits induced by cerebral oligemia of rats [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Male Han-Wistar rats with bilateral damping of carotid arteries (BCCA) [1] |
| Dosage: | 30 mg/kg |
| Administration: | Intraperitoneal injection; 30 mg/kg, once |
| Result: | Showed no effect on GABA or ACh content in either BCCA or sham-operated control rats. Significantly increased swimming speed of BCCA rats in swimming test. Prevented the increasing of escape latency to reach the hidden platform. |
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.